These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37667518)
1. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model. Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518 [TBL] [Abstract][Full Text] [Related]
2. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755 [TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997 [TBL] [Abstract][Full Text] [Related]
5. Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition. Helmer E; Karimian N; Van Assche K; Seghers I; Le Tallec S; Cherala G; Scott G; Namour FS Clin Pharmacol Ther; 2022 Oct; 112(4):901-908. PubMed ID: 35713964 [TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Prakash C; Fan B; Ke A; Le K; Yang H Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634 [TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters. Barth A; Perry CR; Shabbir S; Zamek-Gliszczynski MJ; Thomas S; Dumont EF; Brimhall DB; Nguyen D; Srinivasan M; Swift B Clin Transl Sci; 2023 Apr; 16(4):647-661. PubMed ID: 36642822 [TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors. Kollipara S; Ahmed T; Praveen S Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899 [TBL] [Abstract][Full Text] [Related]
9. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates. Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling. Ji T; Chen X; Yeleswaram S CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332 [TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions. Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206 [TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. Wu F; Krishna G; Surapaneni S Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148 [TBL] [Abstract][Full Text] [Related]
13. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model. Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895 [TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole. Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789 [TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling of Palbociclib. Yu Y; Loi CM; Hoffman J; Wang D J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157 [TBL] [Abstract][Full Text] [Related]
16. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models. Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361 [TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):926-940. PubMed ID: 38482980 [TBL] [Abstract][Full Text] [Related]
18. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Brown HS; Galetin A; Hallifax D; Houston JB Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536 [TBL] [Abstract][Full Text] [Related]
20. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. Bolleddula J; Ke A; Yang H; Prakash C CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]